v3.26.1
Fair Value Measurements - Schedule of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Derivative Liabilities Embedded Derivative | 2029 Notes | 2029 Embedded Derivative        
Liabilities Measured on Recurring Basis        
As of beginning balance $ 93,254 $ 37,226 $ 83,904 $ 51,819
Payment 0   0  
Changes in fair value 59,650 10,867 69,000 (3,726)
As of ending balance 152,904 48,093 152,904 48,093
Derivative Liabilities Embedded Derivative | 2025 Notes | 2029 Embedded Derivative        
Liabilities Measured on Recurring Basis        
As of beginning balance   874   2,915
Changes in fair value   489   (1,552)
As of ending balance   1,363   1,363
ImThera Contingent Consideration Arrangements Liability        
Liabilities Measured on Recurring Basis        
As of beginning balance 102,730 85,140 92,075 84,218
Payment (60,458)   (60,458)  
Changes in fair value (151) 2,787 10,504 3,709
As of ending balance 42,121 87,927 42,121 87,927
ImThera Contingent Consideration Arrangements Liability | Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold        
Liabilities Measured on Recurring Basis        
Changes in fair value $ (1,000) $ 1,500 $ 100 $ 1,800
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Cost of sales Cost of sales Cost of sales Cost of sales
ImThera Contingent Consideration Arrangements Liability | Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Liabilities Measured on Recurring Basis        
Changes in fair value $ 800 $ 1,200 $ 10,400 $ 1,900
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development Research and development Research and development Research and development
Derivative Assets Capped Calls | 2029 Notes | 2029 Capped Calls        
Assets Measured on Recurring Basis        
As of beginning period $ 38,277 $ 17,190 $ 36,551 $ 23,735
Payment 0   0  
Changes in fair value 19,016 4,468 20,742 (2,077)
As of ending period 57,293 21,658 57,293 21,658
Derivative Assets Capped Calls | 2025 Notes | 2029 Capped Calls        
Assets Measured on Recurring Basis        
As of beginning period   805   2,624
Changes in fair value   498   (1,321)
As of ending period   $ 1,303   $ 1,303
Investment in Convertible Notes Receivable        
Assets Measured on Recurring Basis        
As of beginning period 3,000   3,000  
Payment 0   0  
Changes in fair value 0   0  
As of ending period $ 3,000   $ 3,000